Study by 4D Molecular Therapeutics, Inc. (FDMT):

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) — Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. (“4D Molecular” or “the Company”) (NASDAQ: FDMT). Investors who purchased securities of 4D Molecular are encouraged to obtain additional information and assist in the investigation by visiting the Company’s website: bgandg.com/FDMT.

Examination details

On July 17, 2024, 4D Molecular released interim results from its Phase 2 PRISM study of intravitreal 4D-150. Although the company called the results positive, 4D Molecular shares fell approximately 35% in trading the same day.

What’s next?

If you are aware of facts related to this investigation, or if you purchased securities of 4D Molecular, you may assist this investigation by visiting the company’s website: https://bgandg.com/FDMT. You may also contact Peretz Bronstein or his account executive Nathan Miller of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There are no costs for you

We represent investors in class action lawsuits on a contingency basis, meaning we ask the court to reimburse us for our expenses and attorney fees (usually a percentage of the total award) only if we win.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm representing investors in securities fraud class action lawsuits and shareholder actions involving derivatives trading. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Past results do not guarantee similar results.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]